Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Generalized weakness after focal injection of botulin toxin type A (BTA)

Abstract
Data di Pubblicazione:
2011
Citazione:
Generalized weakness after focal injection of botulin toxin type A (BTA) / G., Galassi; C., Orlandi; F., Valzania; G., Albertini; A., Ariatti; Barbieri, Alberto. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - STAMPA. - 257 (Suppl 1):(2011), pp. S175-S175. ( Twentyth Meeting of the European Neurological Society Berlin 19-23/06/2010).
Abstract:
Objective: Botulinum toxin type A (BTA) is established treatment for muscle, autonomic nerve terminal overactivity.BTA is primarily presynaptic neuromuscular blocking agent inducing selective. reversible muscle weakness lasting several months when injected intramuscu1arly.The toxin in therapeutic doses is safe.Generalizcd weakness of distant muscles is seldom reported. BTA is digested ingastrointestinal tract as it forms complex with proteins that protect and stabilize ncurotoximit considered treatment option for gastrointestinal achalasia. Methods: A75 year old diabetic woman developed functional obstructive gastrointestinal symptoms due to esophageal achalasia. She received endoscopically epicardial BTA injection (Botox Aller- gan I00 U).By day 3 patient developed shortness of breath, dysarthria, dysphagia, nasal regurgitation.By day 7 she exhibited respiratory distress.When admitted to ICU (day 8) patient was alert; eye movements were full with normally reactive pupils. There was neck flexor, upper, lower limb weakness graded Z/5-3/5 respectively (MRC scale).Deep jerks were brisk throughout. Results: Blood tests showed anemia; tumor marker titer, autoim- mune screenings, antibody scarch of muscle tyrosin kinase, acetilcholine receptors, voltage gated calcium channels were negative.Brain,total body computed tomography was inconclusive. Three Hz repetitive nerve stimulation(RS)on day 8 showed 25 % decrement of ulnar compound muscle action potential(CMAP). Repeated low rate RS(day I2) revealed up tol8% CMAP decrement before and after activation.No increment was recorded at 20 Hz whereas initial CMAPs were low in amplitude(l—2 mV). Overall findings suggested severe neuromuscular transmission defect. Necdle electromyography (day I2, 45) showed widespread denervation. increased brief duration polyphasia. Oral pyridostigmine bromide(60 mg every 4 hour)was commenced on day 8. Four courses of plasma exchanges (PEX) were given from day 21.By day 48.patient was able to protrude her tongue,to bend upper, lower limbs. By day 5, she developed respiratory failure due to superimposed pneumonia from which she recovered. Conclusions: Our patient exhibited neuromuscular junction (nmj) disorder chronologically related to BTA injection.Electi-ophysiology suggested transmitter release block.The disorder partially responded to oral anticholincsterases and PEX. In our view,pathogencsis was related either to distant effect of BTA or to uncover underlying nmjdisorder.
Tipologia CRIS:
Abstract in Rivista
Keywords:
weakness; botulin toxin type A
Elenco autori:
G., Galassi; C., Orlandi; F., Valzania; G., Albertini; A., Ariatti; Barbieri, Alberto
Autori di Ateneo:
BARBIERI Alberto
Link alla scheda completa:
https://iris.unimore.it/handle/11380/833491
Titolo del libro:
Journal of Neurology
Pubblicato in:
JOURNAL OF NEUROLOGY
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.0.0